Study purposse:  Describe the demographics, risk factors for lung cancer, and baseline Lung Rads score of individuals enrolled in this observational study. Using descriptive statistics, compare the demographics and Lung Rads score of the participants enrolled in this study with those participating in the NLST and NELSON studies. Using descriptive statistics, compare the demographics and Lung Rads score of the participants enrolled in this study with a cohort of participants in the lung screening program at IU HealthParticipants will be recruited by advertisements and at community events. Participants will undergo their lung screening at IU Health fixed lung screening sites or through the IU Health mobile lung screening program.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This study is looking at how flavor-masked foods might be more acceptable to children with autism. Autism spectrum disorder (ASD) is a condition that affects how a person thinks, learns, and experiences their surroundings. The purpose of this study is to see if masking strong tastes and smells of certain nutritious foods, like broccoli sprouts and moringa, can encourage children with autism to try them.All study activities can be completed online at home - no in-person visits or travel is required.We are inviting parents/caregivers of a child aged 3-12 years who is diagnosed with Autism spectrum disorder (ASD) to participate.

This study is a prospective, cohort study to determine the quantitative threshold differences in troponin-I level between hemorrhagic and non-hemorrhagic myocardial infarction (MI).

This phase II clinical trial tests how well pembrolizumab plus enfortumab vedotin prior to and after radical nephroureterectomy works in treating patients with high-risk upper tract urothelial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Enfortumab vedotin (EV) is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Radical nephroureterectomy (RNU) is the surgical removal of a kidney and its ureter. Giving pembrolizumab plus enfortumab vedotin before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed and giving pembrolizumab after surgery may kill any remaining cancer cells. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632